

RECEIVED

SEP 07 2001

TECH CENTER 1600 2900

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

August 31, 2001  
Date

Steven L. Highlander

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Paul McCray et al.

Serial No.: 09-448,613

Filed: November 22, 1999

For: METHODS AND COMPOSITIONS FOR  
INCREASING THE INFECTIVITY OF  
GENE TRANSFER VECTORS

Group Art Unit: 1641

Examiner: R. Schnizer

Atty. Dkt. No.: IOWA:022/SLH

**RESPONSE TO RESTRICTION REQUIREMENT DATED JUNE 1, 2001**

Commissioner for Patents  
Washington, D.C. 20231

Commissioner:

This paper is submitted in response to the Restriction Requirement dated June 1, 2001 for which the date for response was July 1, 2001.

A request for a two-month extension of time to respond is included herewith along with the required fee. This two-month extension will bring the due date to September 1, 2001, which is within the six-month statutory period. Should such request or fee be deficient or absent, consider this paragraph such a request and authorization to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212 10008931 SLH.


In response to the restriction requirement which the Examiner imposed, Applicants elect, without traverse, to prosecute claims 1-37, 48-52 and 70, *i.e.*, the Group I claims.

In response to the restriction requirement which the Examiner imposed, Applicants elect, the election of species comprising a retrovirus (claim 26), a membrane channel (claim 29) and cystic fibrosis (claim 33), and the combination of a hypotonic solution and an ion chelator. The following is a listing of claims reading upon the elected species and the generic claims:

<u>Species</u>	<u>Reading On</u>	<u>Generic</u>
Retrovirus	1-37, 48-52 and 70	1-30, 32-37, 48-51 and 70
Membrane Channel	1-37, 48-52 and 70	1-37, 48-52 and 70
Cystic Fibrosis	1-37, 48-52 and 70	1-37, 48-52 and 70
Hypotonic Soln. + Ion Chelator	1-12, 26-37 and 70	1-12 and 26-37

The Examiner is invited to contact the undersigned attorney at (512) 536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 536-3184

Date: August 31, 2001